Psychedelics Weekly – Research Explained: Ket...

ALS and ketamine therapy are at the center of this conversation with psychiatrist Dr. Michael Alpert and Peter Alberding, who was diagnosed with ALS in late 2023. Alpert is a Boston-area psychiatrist with experience in MDMA-assisted therapy research for PTSD and a private practic ...  Afficher plus

Psychiatrist and psychedelics and bipolar researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treat ...

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ...  Afficher plus

We’re in the midst of a psychedelic renaissance, where this once demonized class of drugs is now front and center receiving attention among entrepreneurs, investors, clinical trials and even patients. In this special conversation, TED Health’s Dr. Shoshana Ungerleider speaks with ...  Afficher plus

Dr. Paul Liknaitsky is the head of clinical psychedelic research at Monash University Australia. He is conducting world-first clinical trials into the use of magic mushrooms and ecstasy to treat depression, anxiety, and PTSD. This is his second time on this podcast to chat about ...  Afficher plus